Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Reducing that frequency could be a competitive advantage against similarly-dosed rivals like Eli Lilly's tirzepatide-based Mounjaro and Zepbound, help patients comply with treatment, and ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Lilly's growth was led by its GLP-1 drugs. For the quarter, revenue for Mounjaro soared 60% year over year to $3.5 billion, while revenue for Zepbound surged from $175.8 million to $1.9 billion.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend growth stocks. Dividend stocks faced a tough year in 2024 as investor focus ...